In this article, we will look at the 10 Best Growth Stocks With Highest Upside Potential.
Growth stocks with large implied upside are getting another look as investors try to separate real earnings momentum from stocks that simply look cheap against analyst target prices.
BlackRock says “Earnings strength is broadening” and points to a “new trend of upward revisions,” while also noting that “non-Mag 7 earnings power may be underappreciated.” In summary, the growth story is no longer only about the largest technology names, which gives investors more room to look for stocks where analyst expectations have not fully caught up. Fidelity says “Tech is still king” and remains “ground zero for earnings growth,” with “technology remains difficult to replace” for investors looking for durable expansion. AllianceBernstein adds that growth stocks still have “long-term growth potential,” supported by “strong earnings and continued AI-related capital spending” and broader “structural growth drivers.”
Against this backdrop, growth stocks with the highest upside potential deserve a closer look. The more interesting names are those where revenue growth, earnings revisions, sector demand, and analyst sentiment are moving in the same direction. With that in mind, let’s take a look at the 10 Best Growth Stocks With Highest Upside Potential.
Our Methodology
We used the Finviz screener to identify stocks that have posted compounded annual revenue growth of over 30% in the past 3 years and whose median analyst price target offers at least 40% upside. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
10. Coinbase Global, Inc. (NASDAQ:COIN)
On July 10, 2026, Coinbase Global, Inc. (NASDAQ:COIN) announced that Paul Grewal had notified the company of his intention to step down as Chief Legal Officer and Secretary, effective July 31. In connection with the resignation, Coinbase expects to appoint Molly Abraham, Vice President, Legal, as General Counsel and Secretary. On July 8, Coinbase and Grewal entered into an advisor agreement under which Grewal will assist with the transition and provide other advisory services from August 1 to October 31. Grewal will receive a lump sum payment equal to three months of current base salary after the advisory period and continued vesting of restricted stock units scheduled to vest on August 20, subject to continued service under the agreement.
On July 9, Citizens analyst Devin Ryan lowered the firm’s price target on Coinbase to $325 from $355 and kept an Outperform rating on the shares.
On July 7, US Tiger upgraded Coinbase to Buy from Hold with a $200 price target, citing a “more constructive view” on Bitcoin’s cycle risk/reward. US Tiger said the largest part of cycle de-risking is already behind us after a roughly 54% drawdown from the October 2025 cycle high, reset on-chain profitability, and roughly three realized-loss capitulation waves.
Coinbase Global, Inc. (NASDAQ:COIN) operates a platform for crypto assets in the United States and internationally.
9. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
On July 10, 2026, Morgan Stanley raised the firm’s price target on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to $400 from $370 and kept an Equal Weight rating on the shares.
On July 9, Raymond James raised the firm’s price target on Alnylam to $468 from $420 and kept an Outperform rating on the shares. Raymond James said Ionis’ (IONS) failed Phase 3 ATTR-CM trial strengthens Alnylam’s competitive position by reducing a key rival to its TTR silencer franchise and improving the outlook for pricing. The firm also noted that the results may raise some risk for Alnylam’s next-generation nucresiran trial in patients receiving background tafamidis.
On June 29, H.C. Wainwright lowered the firm’s price target on Alnylam to $470 from $510 and kept a Buy rating on the shares. H.C. Wainwright reduced near-term estimates for Amvuttra but continued to estimate Alnylam’s TTR franchise growing to over $20B in annual revenues by 2040.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Hedge Fund Resource Center